Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Relmada Therapeutics (RLMD) Operating Expenses (2016 - 2026)

Relmada Therapeutics has reported Operating Expenses over the past 3 years, most recently at $3121.0 for Q1 2014.

  • Quarterly Operating Expenses fell 32.56% to $3121.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $37456.0 through Feb 2014, up 45.85% year-over-year, with the annual reading at $59.1 million for FY2025, 29.55% down from the prior year.
  • Operating Expenses was $3121.0 for Q1 2014 at Relmada Therapeutics, down from $14538.0 in the prior quarter.
  • Over five years, Operating Expenses peaked at $19797.0 in Q2 2013 and troughed at $2589.0 in Q2 2012.
  • The 3-year median for Operating Expenses is $9146.0 (2012), against an average of $9019.7.
  • Year-over-year, Operating Expenses skyrocketed 664.66% in 2013 and then tumbled 32.56% in 2014.
  • A 3-year view of Operating Expenses shows it stood at $9319.0 in 2012, then surged by 56.0% to $14538.0 in 2013, then tumbled by 78.53% to $3121.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Operating Expenses are $3121.0 (Q1 2014), $14538.0 (Q4 2013), and $19797.0 (Q2 2013).